eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2019
vol. 23
 
Share:
Send email
Share:
abstract:
Original paper

18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study

Jarosław Czyż
1
,
Bogdan Małkowski
2
,
Artur Jurczyszyn
3
,
Norbert Grząśko
4
,
Rita Łopatto
2
,
Monika Olejniczak
5
,
Adriana Czyż
1
,
Anna Jachalska
6

  1. Department of Haematology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
  2. Department of Nuclear Medicine, Professor Franciszek Lukaszczyk Oncology Centre in Bydgoszcz, Bydgoszcz, Poland
  3. Department of Haematology, Jagiellonian University Medical College, Krakow, Poland
  4. Department of Haematology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
  5. Department of Oncology, Professor Franciszek Lukaszczyk Oncology Centre in Bydgoszcz, Bydgoszcz, Poland
  6. Department of Haematology, Dr. Jan Biziel University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Poland
Contemp Oncol (Pozn) 2019; 23 (1): 23-31
DOI: https://doi.org/10.5114/wo.2019.83342
Online publish date: 2019/03/04
View full text Get citation
 
PlumX metrics:
Aim of the study
The aim of this study was to analyse the diagnostic accuracy of “18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT tracer in multiple mye­loma.

Material and methods
The analysed group included: patients with newly diagnosed active myeloma (eight patients); in very good partial remission or complete remission (VGPR or CR) after treatment (nine patients); and with active disease after relapse (15 patients).

Results
In patients with newly diagnosed myeloma, 64 lesions were found using CT and 83 lesions using 18F-FET. In six patients, the number of lesions using CT and 18F-FET was the same, and two had more lesions with the 18F-FET than with the CT. Patients in VGPR or CR had no FET-positive lesions. Fourteen out of 15 patients with active relapsed myeloma had 47 FET-positive lesions, CT assessment of the same group showed 282 lesions. In one patient with relapse soft tissue mass was found with 18F-FET but not with CT.

Conclusions
18F-FET can be a promising alternative to 18F-FDG PET/CT for myeloma-related bone disease diagnosis.

keywords:

multiple myeloma, 18F-FET, 18F-FDG PET/CT
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.